Wells Fargo & Company Cellectar Biosciences, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$3.5 - $6.9 $105 - $207	30 Added 8.22%	395 $0
Q1 2022 May 16, 2022	BUY	$4.6 - $7.8 $4 - $7	1 Added 0.27%	365 $0
Q4 2021 Feb 14, 2022	SELL	$6.1 - $10.2 $18,184 - $30,406	-2,981 Reduced 89.12%	364 $0
Q3 2021 Nov 15, 2021	BUY	$8.2 - $12.4 $188 - $285	23 Added 0.69%	3,345 $3,000
Q2 2021 Aug 16, 2021	BUY	$11.8 - $18.2 $129 - $200	11 Added 0.33%	3,322 $4,000
Q1 2021 May 13, 2021	BUY	$15.2 - $25.0 $2,340 - $3,850	154 Added 4.88%	3,311 $6,000
Q4 2020 Feb 09, 2021	BUY	$11.2 - $27.7 $112 - $277	10 Added 0.32%	3,157 $6,000
Q3 2020 Nov 05, 2020	BUY	$10.6 - $16.6 $1,303 - $2,041	123 Added 4.07%	3,147 $4,000
Q2 2020 Aug 13, 2020	SELL	$10.3 - $17.3 $10,300 - $17,300	-1,000 Reduced 24.85%	3,024 $4,000
Q1 2020 May 14, 2020	BUY	$11.0 - $31.7 $44,264 - $127,560	4,024 New	4,024 $5,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.